Showcases Stock ranks Forex

Catalyst Pharm Inc (CPRX)
16.12  0.1 (0.62%) 03-24 16:00
Open: 15.88 Pre. Close: 16.02
High: 16.165 Low: 15.64
Volume: 1,383,056 Market Cap: 1,703(M)
Stock Technical Analysis
Target: Six months: 19.60
One year: 22.89
Support: Support1: 14.98
Support2: 13.87
Resistance: Resistance1: 16.78
Resistance2: 19.60
Pivot: 15.47
Moving Averages: MA(5): 16.26
MA(20): 15.44
MA(100): 16.49
MA(250): 12.61
MACD: MACD(12,26): 0.08
Signal(12,26,9): -0.10
%K %D: %K(14,3): 77.21
%D(3): 82.98
RSI: RSI(14): 55.08
52-Week: High: 22.11
Low: 6.15
Change(%): 94.7
Average Vol(K): 3-Month: 2327
10-Days: 2322
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 16.178 - 16.258 16.258 - 16.339
Low: 15.454 - 15.536 15.536 - 15.619
Close: 15.986 - 16.118 16.118 - 16.252
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ CPRX ] has closed below upper band by 26.3%. Bollinger Bands are 15.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Stock chart
Stock News
Sun, 26 Mar 2023
First Hawaiian Bank sells Catalyst Pharmaceuticals, Inc. stock ... - Best Stocks

Sat, 25 Mar 2023
Alicia Grande Sells 41784 Shares of Catalyst Pharmaceuticals, Inc ... - MarketBeat

Fri, 24 Mar 2023
First Hawaiian Bank Cuts Stock Position in Catalyst Pharmaceuticals ... - MarketBeat

Thu, 23 Mar 2023
Robeco Institutional Asset Management B.V. Acquires New ... - MarketBeat

Wed, 22 Mar 2023 featured highlights include Catalyst Pharmaceuticals, Terex and Arista Networks - Yahoo Finance

Tue, 21 Mar 2023
Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You ... - Nasdaq

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 104.07
Shares Float (M) 93.28
% Held by Insiders 5.97
% Held by Institutions 82.04
Shares Short (K) 10370
Shares Short Prior Month (K) 8630
Stock Financials
EPS 0.650
Book Value (p.s.) 2.850
Profit Margin 38.78
Operating Margin 47.54
Return on Assets (ttm) 20.8
Return on Equity (ttm) 32.8
Qtrly Rev. Growth 58.6
Gross Profit (p.s.) 1.538
Sales Per Share 2.058
EBITDA (p.s.) 0.990
Qtrly Earnings Growth 156.30
Operating Cash Flow (M) 116.05
Levered Free Cash Flow (M) 89.70
Stock Valuation
PE Ratio 24.80
PEG Ratio
Price to Book value 5.66
Price to Sales 7.83
Price to Cash Flow 14.46
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android